BioSpace News Archive

Intercept Pharmaceuticals, Inc. announced that it has entered into privately negotiated agreements with certain of the holders of its existing 3.25% Convertible Senior Notes due 2023 and 2.00% Convertible Senior Notes due 2026 to exchange an aggregate of $306.5 million principal amount of 2023 Notes and an aggregate of $114.7 million principal amount of 2026 Notes for a newly issued series of Convertible Senior Secured Notes due 2026.

Avinger, Inc., a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease, reported results for the second quarter ended June 30, 2021.

Codex DNA, Inc., a pioneer in automated benchtop synthetic biology systems, reported financial results for the second quarter ended June 30, 2021.

Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation platform technologies, today announced that it will participate in the following upcoming virtual investor conferences.

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today provided a corporate update and reported financial results for the second quarter ended June 30, 2021.

Scholar Rock, a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, reported financial results for the second quarter ended June 30, 2021, and highlighted recent progress and upcoming milestones for its pipeline programs.

Jaguar Health, Inc. announced that the Company investor webcast scheduled for Friday, August 13, 2021 will take place at 8:00 a.m. Eastern Time instead of 8:30 a.m.

InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today the Investigational New Drug (IND) approval of its Bruton’s tyrosine kinase (BTK) inhibitor orelabrutinib by China National Medical Products Administration (NMPA) for starting phase II clinical trial in primary immune thrombocytopenia (ITP) in China.

Cardinal Health (NYSE: CAH) today announced its efforts to commercialize and broaden access to over-the-counter rapid COVID-19 tests through partnerships with Abbott and Quidel Corporation (“Quidel”).

Vecna Technologies, a leading provider of healthcare information technologies focused on patient intake, clinical surveillance and telepresence robotics, announced today the launch of the Vecna HealthPass Mobile App at the HIMSS Global Health Conference and Exhibition August 9-13, 2021 in Las Vegas, Nevada.